FLI1 Gene Platelet Dense Granule Secretion Defect Excessive Bleeding Genetic Test
Components: FLI1 Gene Platelet Dense Granule Secretion Defect Excessive Bleeding Genetic Test
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Hematology
Doctor: Hematologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for FLI1 Gene Platelet Dense Granule Secretion Defect, Excessive Bleeding NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with FLI1 Gene Platelet Dense Granule Secretion Defect, Excessive Bleeding NGS Genetic DNA Test gene FLI1.
Test Details: The FLI1 gene is responsible for encoding a protein called Friend leukemia integration 1 transcription factor (FLI1). This protein is involved in the development of blood cells and plays a role in the regulation of platelet dense granule secretion. Platelet dense granules contain various molecules that are released upon platelet activation, including calcium, serotonin, and adenosine diphosphate (ADP). These molecules are important for the formation of blood clots, which helps prevent excessive bleeding. A defect in the FLI1 gene can lead to impaired platelet dense granule secretion. This means that the platelets are unable to release the necessary molecules to form effective blood clots. As a result, individuals with this defect may experience excessive bleeding, even from minor injuries or surgeries. To diagnose a platelet dense granule secretion defect caused by a mutation in the FLI1 gene, a next-generation sequencing (NGS) genetic test can be performed. NGS is a high-throughput method that allows for the simultaneous analysis of multiple genes or even the entire genome. It can detect specific mutations or variations in the FLI1 gene that may be responsible for the platelet dysfunction. By identifying the specific genetic mutation causing the defect, healthcare professionals can provide a more accurate diagnosis and develop targeted treatment strategies. This may include the use of medications that can enhance platelet function or the administration of platelet transfusions in severe cases. It is important to consult with a genetic counselor or healthcare provider to discuss the appropriateness and implications of genetic testing for platelet dense granule secretion defects. They can provide more information on the benefits, limitations, and potential risks associated with the testing process.
| Test Name | FLI1 Gene Platelet dense granule secretion defect excessive bleeding Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Hematology |
| Doctor | Hematologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for FLI1 Gene Platelet dense granule secretion defect, excessive bleeding NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with FLI1 Gene Platelet dense granule secretion defect, excessive bleeding NGS Genetic DNA Test gene FLI1 |
| Test Details |
The FLI1 gene is responsible for encoding a protein called Friend leukemia integration 1 transcription factor (FLI1). This protein is involved in the development of blood cells and plays a role in the regulation of platelet dense granule secretion. Platelet dense granules contain various molecules that are released upon platelet activation, including calcium, serotonin, and adenosine diphosphate (ADP). These molecules are important for the formation of blood clots, which helps prevent excessive bleeding. A defect in the FLI1 gene can lead to impaired platelet dense granule secretion. This means that the platelets are unable to release the necessary molecules to form effective blood clots. As a result, individuals with this defect may experience excessive bleeding, even from minor injuries or surgeries. To diagnose a platelet dense granule secretion defect caused by a mutation in the FLI1 gene, a next-generation sequencing (NGS) genetic test can be performed. NGS is a high-throughput method that allows for the simultaneous analysis of multiple genes or even the entire genome. It can detect specific mutations or variations in the FLI1 gene that may be responsible for the platelet dysfunction. By identifying the specific genetic mutation causing the defect, healthcare professionals can provide a more accurate diagnosis and develop targeted treatment strategies. This may include the use of medications that can enhance platelet function or the administration of platelet transfusions in severe cases. It is important to consult with a genetic counselor or healthcare provider to discuss the appropriateness and implications of genetic testing for platelet dense granule secretion defects. They can provide more information on the benefits, limitations, and potential risks associated with the testing process. |
